tradingkey.logo

Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2

ReutersJun 4, 2025 11:16 AM

Design Therapeutics Inc DSGN.O:

  • DESIGN THERAPEUTICS ANNOUNCES START OF FRIEDREICH ATAXIA PATIENT DOSING EX-U.S. IN ITS RESTORE-FA PHASE 1/2 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216P2

  • DESIGN THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON IND APPLICATION FOR U.S. SITES

  • DESIGN THERAPEUTICS INC - NO ADVERSE EVENTS REPORTED IN DT-216P2 ADMINISTRATION

  • DESIGN THERAPEUTICS INC - PHASE 1 SINGLE-ASCENDING DOSE TRIAL SHOWS DT-216P2 WELL-TOLERATED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI